Showing 3951-3960 of 4063 results for "".
- FDA Clears Fish-Skin Technology to Heal Human Woundshttps://practicaldermatology.com/news/20131107-fda_clears_fish-skin_technology_to_heal_human_wounds/2459421/Kerecis Limited announced has received FDA 510(k) clearance from the Food and Drug Administration (FDA) to market a proprietary fish-skin, Omega3, tissue-regeneration technology for the treatment of chronic wounds in the US. The technology, marketed under the name MariGen Omega3, is indicated for th
- Humira Found Effective for Hidradentis Suppurativahttps://practicaldermatology.com/news/20131011-humira_found_effective_for_hidradentis_suppurativa/2459436/Results from a post-hoc analysis of an investigational Phase II study found that Humira (adalimumab, AbbVie) induced significant response rate in adult patients with moderate to severe hidradenitis suppurativa (HS) after 16 weeks of therapy. Researchers used the HS-Physician Global Assessment (HS-P
- Cimzia FDA Approved to Treat Active Psoriatic Arthritis in Adultshttps://practicaldermatology.com/news/20131001-cimzia_receives_fda_approval_to_treat_adults_with_active_psoriatic_arthritis/2459446/The FDA recently approved UCB's Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA). The FDA approval of Cimzia for active PsA is based on data from the RAPID-PsA study, an ongoing, Phase III, multicenter, randomized,
- Dermatologist Launches Sunscreen with Zinc, Anti-cancer Agentshttps://practicaldermatology.com/news/20130926-dermatologist_launches_sunscreen_with_zinc_anti-cancer_agents/2459449/Rejuve MD is an anti-aging sunblock that includes only Zinc Oxide as the sunblock without the need to use chemical sunscreens. Rejuve MD sunblock is also unique in that it not only prevents UV radiation sun damage from both UVB but also UVA light and it also has anti-aging and anti-cancer forming na
- Data for PV-10 in Melanoma to be Presented at European Cancer Congresshttps://practicaldermatology.com/news/20130913-data_for_pv-10_in_melanoma_to_be_presented_at_european_cancer_congress/2459461/Analysis of data from Provectus Pharmaceuticals, Inc.'s completed Phase 2 study of intralesional PV-10 in metastatic melanoma will be presented at the upcoming European Cancer Congress (ECCO 17- ESMO-38 - ESTRO 32), taking place September 27 through
- Agenda Set for 2013 Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20130830-agenda_set_for_2013_cosmetic_surgery_forum/2459471/The 2013 Cosmetic Surgery Forum, taking place from December 5 – 7 at the Aria Resort and Casino in Las Vegas, has recently unveiled its agenda. According to course director Joel Schlessinger, MD, this year's meeting promises offer attendees a host of new sessions on injectables and newer methods of
- Alphaeon Acquires US License To Teoxane Laboratories' Dermal Fillers And Cosmeceutical Productshttps://practicaldermatology.com/news/20130802-alphaeon_acquires_us_license_to_teoxane_laboratories_dermal_fillers_and_cosmeceutical_products/2459484/Alphaeon Corporation, a wholly-owned subsidiary of Strathspey Crown Holdings, LLC, has acquired an exclusive US license for the full line of products from Teoxane Laboratories. Containing 100 percent non-animal origin, resorbable hyaluronic acid, Teoxane's dermal fillers are currently available in m
- Galen Acquires Local Dermal Analgesia Drug Synerahttps://practicaldermatology.com/news/20130716-galen_acquires_local_dermal_analgesia_drug_synera/2459495/Galen, a Northern Ireland based pharmaceutical company, has acquired Synera® (lidocaine 70mg/tetracaine 70mg) topical patch from ZARS Pharma, Inc., a wholly owned subsidiary of Nuvo Research Inc. Synera® is indicated for use on intact skin t
- Investigational Psoriasis Agent On Track for Regulatory Submission This Yearhttps://practicaldermatology.com/news/20130708-investigational_psoriasis_agent_on_track_for_regulatory_submission_this_year/2459501/Results from a Phase III trial showed that the experimental drug secukinumab (Novartis) showed superiority to etanercept (Enbrel, Amgen) at clearing skin in patients with moderate-to-severe plaque psoriasis. The FIXTURE trial, which randomized 1,307 patients with moderate-to-severe plaque psoriasis,
- Naftin Gel 2% Approved for Interdigital-Type Tinea Pedishttps://practicaldermatology.com/news/20130702-naftin_gel_2_approved_for_interdigital-type_tinea_pedis/2459507/The FDA approved Naftin (naftifine HCl) Gel 2% for the treatment of interdigital-type tinea pedis from Merz North America. Naftin Gel 2% improves on the current formulation of Naftin Gel 1% by delivering the efficacy of naftifine hydochloride with